Non-viral vectors for cancer therapy.
Cancers are diverse and often resistant to therapeutic strategies. Gene therapy has yet to meet the promise of a breakthrough in cancer therapy. There are several barriers to overcome in cancer gene therapy. One of the biggest challenges is the design of appropriate vectors. Numerous viral and non-viral methods for gene transfer have been developed for human gene therapy, but both viral and non-viral vectors have limitations and advantages. In this review article, recent improvements in the development of non-viral vectors for delivering gene therapy for the treatment of cancer will be discussed.
Kaneda
Yasufumi
Y
Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. kaneday@gts.med.osaka-u.ac.jp
Tabata
Yasuhiko
Y
D000818:Animals; D002945:Cisplatin / Q000378:metabolism / Q000494:pharmacology; D018274:Electroporation / Q000379:methods; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D008081:Liposomes / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D008819:Mice, Nude; D008954:Models, Biological; D009369:Neoplasms / Q000378:metabolism / Q000628:therapy*; D011108:Polymers / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D029082:Sendai virus / Q000378:metabolism; D014465:Ultrasonics
D008081:Liposomes; D011108:Polymers; D002945:Cisplatin